Compare Stocks: KYTX, AGIO, ABCL, and DMRA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABCL AbCellera Biologics	$6.93 +6.1%	$6.22	$2.74 ▼ $8.44	$2.00B	1.2	5.02 million shs	6.42 million shs
AGIO Agios Pharmaceuticals	$32.27 +1.0%	$34.75	$22.24 ▼ $46.00	$1.91B	0.58	1.19 million shs	1.40 million shs
DMRA Damora Therapeutics, Inc. Common Stock	$29.92 +0.1%	$26.46	$2.45 ▼ $38.33	$1.84B	1.47	445,687 shs	197,365 shs
KYTX Kyverna Therapeutics	$7.96 +2.7%	$8.06	$2.80 ▼ $13.67	$471.16M	1.93	1.02 million shs	431,396 shs

Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABCL AbCellera Biologics	+6.13%	+21.37%	-2.39%	+32.25%	+68.20%
AGIO Agios Pharmaceuticals	+1.00%	+7.50%	-24.53%	+16.12%	-14.45%
DMRA Damora Therapeutics, Inc. Common Stock	+0.13%	+3.21%	+8.68%	+23.84%	+780.00%
KYTX Kyverna Therapeutics	+2.71%	+9.04%	-19.68%	-14.87%	+139.04%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABCL AbCellera Biologics	$6.93 +6.1%	$6.22	$2.74 ▼ $8.44	$2.00B	1.2	5.02 million shs	6.42 million shs
AGIO Agios Pharmaceuticals	$32.27 +1.0%	$34.75	$22.24 ▼ $46.00	$1.91B	0.58	1.19 million shs	1.40 million shs
DMRA Damora Therapeutics, Inc. Common Stock	$29.92 +0.1%	$26.46	$2.45 ▼ $38.33	$1.84B	1.47	445,687 shs	197,365 shs
KYTX Kyverna Therapeutics	$7.96 +2.7%	$8.06	$2.80 ▼ $13.67	$471.16M	1.93	1.02 million shs	431,396 shs

Don't Wait for the OpenAI IPO

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABCL AbCellera Biologics	+6.13%	+21.37%	-2.39%	+32.25%	+68.20%
AGIO Agios Pharmaceuticals	+1.00%	+7.50%	-24.53%	+16.12%	-14.45%
DMRA Damora Therapeutics, Inc. Common Stock	+0.13%	+3.21%	+8.68%	+23.84%	+780.00%
KYTX Kyverna Therapeutics	+2.71%	+9.04%	-19.68%	-14.87%	+139.04%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABCL AbCellera Biologics	2.67	Moderate Buy	$9.40	35.64% Upside
AGIO Agios Pharmaceuticals	2.40	Hold	$41.25	27.83% Upside
DMRA Damora Therapeutics, Inc. Common Stock	2.92	Moderate Buy	$44.00	47.06% Upside
KYTX Kyverna Therapeutics	2.67	Moderate Buy	$30.00	276.88% Upside

Current Analyst Ratings Breakdown

Latest KYTX, AGIO, ABCL, and DMRA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/7/2026	AGIO Agios Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$31.00 ➝ $34.00
8/6/2026	ABCL AbCellera Biologics	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$8.00 ➝ $9.00
8/6/2026	ABCL AbCellera Biologics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$11.00 ➝ $12.00
7/31/2026	AGIO Agios Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$46.00 ➝ $52.00
7/31/2026	AGIO Agios Pharmaceuticals	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$41.00 ➝ $39.00
7/30/2026	AGIO Agios Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$52.00 ➝ $55.00
7/30/2026	DMRA Damora Therapeutics, Inc. Common Stock	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$35.00 ➝ $40.00
7/27/2026	DMRA Damora Therapeutics, Inc. Common Stock	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$50.00
7/21/2026	AGIO Agios Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$54.00 ➝ $52.00
7/21/2026	DMRA Damora Therapeutics, Inc. Common Stock	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$45.00
7/17/2026	ABCL AbCellera Biologics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)

(Data available from 8/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABCL AbCellera Biologics	$75.13M	28.28	N/A	N/A	$2.92 per share	2.37
AGIO Agios Pharmaceuticals	$54.03M	35.66	N/A	N/A	$17.19 per share	1.88
DMRA Damora Therapeutics, Inc. Common Stock	N/A	N/A	N/A	N/A	($110.11) per share	N/A
KYTX Kyverna Therapeutics	N/A	N/A	N/A	N/A	$3.85 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABCL AbCellera Biologics	-$146.41M	-$0.48	N/A	N/A	N/A	-248.83%	-17.49%	-12.36%	N/A
AGIO Agios Pharmaceuticals	-$412.78M	-$7.01	N/A	N/A	N/A	-418.24%	-35.67%	-33.06%	N/A
DMRA Damora Therapeutics, Inc. Common Stock	-$209.84M	-$5.58	N/A	N/A	N/A	N/A	-428.30%	-114.62%	N/A
KYTX Kyverna Therapeutics	-$161.31M	-$3.28	N/A	N/A	N/A	N/A	-81.88%	-64.87%	8/11/2026 (Estimated)

Latest KYTX, AGIO, ABCL, and DMRA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	KYTX Kyverna Therapeutics	-$0.67	N/A	N/A	N/A	N/A	N/A
8/5/2026	Q2 2026	ABCL AbCellera Biologics	-$0.1640	-$0.18	-$0.0160	-$0.18	$7.85 million	$4.05 million
7/30/2026	Q2 2026	AGIO Agios Pharmaceuticals	-$1.65	-$1.69	-$0.04	-$1.69	$26.40 million	$44.75 million
5/13/2026	Q1 2026	DMRA Damora Therapeutics, Inc. Common Stock	-$0.3878	-$0.62	-$0.2322	-$0.62	N/A	N/A
5/12/2026	Q1 2026	KYTX Kyverna Therapeutics	-$0.75	-$0.66	+$0.09	-$0.66	N/A	N/A
5/11/2026	Q1 2026	ABCL AbCellera Biologics	-$0.22	-$0.14	+$0.08	-$0.14	$5.41 million	$8.32 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABCL AbCellera Biologics	N/A	N/A	N/A	N/A	N/A
AGIO Agios Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
DMRA Damora Therapeutics, Inc. Common Stock	N/A	N/A	N/A	N/A	N/A
KYTX Kyverna Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABCL AbCellera Biologics	N/A	12.77	14.05
AGIO Agios Pharmaceuticals	N/A	10.22	9.79
DMRA Damora Therapeutics, Inc. Common Stock	N/A	22.49	22.48
KYTX Kyverna Therapeutics	0.13	8.15	8.15

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABCL AbCellera Biologics	61.42%
AGIO Agios Pharmaceuticals	N/A
DMRA Damora Therapeutics, Inc. Common Stock	14.20%
KYTX Kyverna Therapeutics	18.08%

Insider Ownership

Company	Insider Ownership
ABCL AbCellera Biologics	28.40%
AGIO Agios Pharmaceuticals	5.40%
DMRA Damora Therapeutics, Inc. Common Stock	0.40%
KYTX Kyverna Therapeutics	17.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABCL AbCellera Biologics	500	306.61 million	218.65 million	Optionable
AGIO Agios Pharmaceuticals	390	59.70 million	56.48 million	Optionable
DMRA Damora Therapeutics, Inc. Common Stock	40	61.55 million	61.31 million	No Data
KYTX Kyverna Therapeutics	96	60.79 million	50.10 million	Optionable

KYTX, AGIO, ABCL, and DMRA Headlines

Recent News About These Companies

Kyverna Therapeutics (KYTX) Expected to Post Quarterly Earnings on Tuesday

August 4, 2026 | marketbeat.com

Kyverna Therapeutics: 'Strong Buy' On ElevateBio Manufacturing Deal And RA Program Advancement

July 29, 2026 | seekingalpha.com

Kyverna secures long-term miv-cel manufacturing partnership

July 27, 2026 | tipranks.com

Kyverna Therapeutics and ElevateBio Enter into Commercial Manufacturing and Supply Agreement for Miv-cel

July 27, 2026 | globenewswire.com

Kyverna’s KYSA-8 Trial Completion Puts Autoimmune Cell Therapy in Investor Focus

July 25, 2026 | theglobeandmail.com

Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Receives Consensus Rating of "Moderate Buy" from Analysts

July 20, 2026 | marketbeat.com

Kyverna Therapeutics Sinks 13%: Here’s Why

July 11, 2026 | aol.comA

Kyverna Therapeutics Sinks 13%: Here's Why

July 10, 2026 | 247wallst.com

Kyverna Therapeutics (NASDAQ:KYTX) Shares Down 11.1% - Time to Sell?

July 10, 2026 | marketbeat.com

Kyverna Therapeutics’ (KYTX) Insights into Stiff Person Syndrome and Beyond

July 9, 2026 | finance.yahoo.com

Kyverna Therapeutics Amends Term Loan, Extends Capital Access

July 9, 2026 | tipranks.com

Kyverna Therapeutics, Inc. $KYTX Shares Bought by AIGH Capital Management LLC

July 9, 2026 | marketbeat.com

Kyverna Therapeutics: The Autoimmune CAR T Beachhead Is Bigger Than SPS

July 6, 2026 | seekingalpha.com

Kyverna Therapeutics Appoints Ritesh Srivastava as Chief Legal and Compliance Officer, Adding Leadership Strength to Support Commercial-Stage Transition

June 22, 2026 | globenewswire.com

Kyverna Therapeutics, Inc. (KYTX) Presents at Jefferies Global Healthcare Conference 2026 - Slideshow

June 5, 2026 | seekingalpha.com

Kyverna Therapeutics Highlights Updated Miv-cel Data at EULAR Demonstrating Substantial Reduction in Disease Activity in ACPA-Positive, Treatment Refractory Rheumatoid Arthritis

June 3, 2026 | globenewswire.com $https://www.globenewswire.com/news-release/2026/06/03/3305974/0/en/kyverna-therapeutics-highlights-updated-miv-cel-data-at-eular-demonstrating-substantial-reduction-in-disease-activity-in-acpa-positive-treatment-refractory-rheumatoid-arthritis.html$

Kyverna Therapeutics Stockholders Approve Directors and Auditor

June 2, 2026 | tipranks.com

Kyverna Therapeutics, Inc.: Kyverna Therapeutics Names Greg Martini as Chief Financial Officer

May 19, 2026 | finanznachrichten.de

Kyverna Therapeutics Names Gregory Martini as New CFO

May 18, 2026 | tipranks.com

Kyverna Therapeutics Names Greg Martini as Chief Financial Officer

May 18, 2026 | globenewswire.com

Kyverna Therapeutics to Present at Upcoming Investor Conferences

May 14, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

KYTX, AGIO, ABCL, and DMRA Company Descriptions

AbCellera Biologics NASDAQ:ABCL

$6.93 +0.40 (+6.13%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$7.64 +0.71 (+10.25%)

As of 08/7/2026 07:59 PM Eastern

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.

Agios Pharmaceuticals NASDAQ:AGIO

$32.27 +0.32 (+1.00%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$32.27 +0.00 (+0.00%)

As of 08/7/2026 07:48 PM Eastern

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Damora Therapeutics, Inc. Common Stock NASDAQ:DMRA

$29.92 +0.04 (+0.13%)

As of 08/7/2026 04:00 PM Eastern

Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.

Kyverna Therapeutics NASDAQ:KYTX

$7.96 +0.21 (+2.71%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$8.02 +0.06 (+0.75%)

As of 08/7/2026 07:34 PM Eastern

Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical stage to treat multiple autoimmune diseases. In addition, it is developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease that includes Crohn's disease and ulcerative colitis. Kyverna Therapeutics, Inc. has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product; and with Kite to research and develop programs for the treatment, diagnosis, and prevention of autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest KYTX, AGIO, ABCL, and DMRA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest KYTX, AGIO, ABCL, and DMRA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

KYTX, AGIO, ABCL, and DMRA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

KYTX, AGIO, ABCL, and DMRA Company Descriptions

AbCellera Biologics NASDAQ:ABCL

Agios Pharmaceuticals NASDAQ:AGIO

Damora Therapeutics, Inc. Common Stock NASDAQ:DMRA

Kyverna Therapeutics NASDAQ:KYTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest KYTX, AGIO, ABCL, and DMRA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest KYTX, AGIO, ABCL, and DMRA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

KYTX, AGIO, ABCL, and DMRA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

KYTX, AGIO, ABCL, and DMRA Company Descriptions

AbCellera Biologics NASDAQ:ABCL

Agios Pharmaceuticals NASDAQ:AGIO

Damora Therapeutics, Inc. Common Stock NASDAQ:DMRA

Kyverna Therapeutics NASDAQ:KYTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools